Regeneron Pharmaceuticals Inc is to appeal against a decision of the European Patent Office (EPO) to revoke its patent for transgenic mouse technology, a patent that was successfully challenged by Kymab Ltd of the UK. ---Subscribe to MedNous to access this article--- Company News IPR & Legal